Amgen and Allergan today announced positive topline results of a combined phase 1 and phase 3 study evaluating ABP 798, a proposed biosimilar rituximab, in comparison with the reference Rituxan in patients with rheumatoid arthritis.
Amgen and Allergan today announced positive topline results of a combined phase 1 and phase 3 study evaluating ABP 798, a proposed biosimilar rituximab, in comparison with the reference Rituxan in patients with rheumatoid arthritis (RA).
The study enrolled 311 patients with RA to receive either ABP 798 (n = 104), US-sourced reference rituximab (n = 103), or EU-sourced reference rituximab (n = 104). The study’s duration was 48 weeks, and included a single transition for patients receiving the US-licensed reference to the proposed biosimilar.
The study’s primary endpoint was pharmacokinetic (PK) similarity between the reference and the proposed biosimilar. The PK endpoints evaluated were the area under the serum concentration—time curve and maximum serum concentration, and the drug makers state that both fell within the prespecified equivalence margin.
Equivalence in efficacy was measured by the change from baseline in Disease Activity Score in a count of 28 joints, measured with C-reactive protein, at week 24. According to Amgen and Allergan, “equivalent efficacy was established.” Furthermore, safety and immunogenicity were both similar among the 3 arms of the study.
“Results from this study show pharmacokinetic and clinical equivalence between ABP 798 and rituximab, further demonstrating Amgen's commitment to providing patients with access to high-quality, biological therapies,” said David M. Reese, MD, executive vice president of research and development at Amgen, in a statement. "We look forward to continuing to leverage our experience and expertise in biotechnology to bring more biosimilars to patients."
The companies noted that they are also currently undertaking another study intended to support regulatory applications; the second study is being conducted in patients with non-Hodgkin lymphoma.
If eventually approved, the biosimilar could compete not only with reference rituximab but also with Celltrion and Teva’s biosimilar, Truxima, which is now approved in both the United States and European Union (where it is also approved under the names Rituzena, Ritemvia, and Blitzima), and Sandoz’s biosimilar, approved in the European Union under the names Riximyo and Rixathon.
While it is not yet clear which indications Amgen and Allergan will seek for the biosimilar, if approved in inflammatory disease indications, ABP 798 could provide an option for US patients with inflammatory diseases who are not served by Truxima; when the biosimilar was approved in late 2018, it was only granted indications in oncology. According to a representative from Celltrion, the “skinny label” was a response to challenges in the patent landscape.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.